海翔药业：关于参投公司创新药NWRD08注射液完成Ⅱ期临床首例受试者入组的自愿性信息披露公告

Core Viewpoint - Haisheng Pharmaceutical announced the initiation of the Phase II clinical trial for China's first on-demand tumor therapeutic vaccine, NWRD08 injection, developed by its invested company, Nuo Wei Biotechnology [2] Group 1 - Haisheng Pharmaceutical received a notification from its fund management subsidiary, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [2] - The clinical trial for NWRD08 has officially started at Peking Union Medical College Hospital and several other hospitals [2] - The first subject has been enrolled and administered the vaccine as part of the clinical trial [2]